SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Mayne Pharma Ventures Pty Ltd., et al. – ‘4’ for 1/15/21 re: Inhibitor Therapeutics, Inc.

On:  Tuesday, 1/19/21, at 1:50pm ET   ·   For:  1/15/21   ·   Accession #:  1104659-21-5226   ·   File #:  1-13467

Previous ‘4’:  ‘4’ on 7/20/20 for 7/15/20   ·   Latest ‘4’:  This Filing

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/19/21  Mayne Pharma Ventures Pty Ltd.    4                      1:9K   Inhibitor Therapeutics, Inc.      Toppan Merrill/FA
          Mayne Pharma International Pty Ltd.
          Mayne Pharma Group Ltd.

Statement of Changes in Beneficial Ownership of Securities by an Insider   —   Form 4   —   SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 4           Ownership Document -- tm213575d1_4.xml/3.6          HTML      3K


        

This ‘4’ Document is an XML Data File that may be rendered in various formats:

  Form 4    –   Plain Text   –  SEC Website  –  EDGAR System  –    XML Data    –  <?xml?> File
 
 
XML Data rendering:  Ownership Document
 
                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<ownershipDocument>
<schemaVersion> X0306 </schemaVersion>
<documentType> 4 </documentType>
<periodOfReport> 2021-01-15 </periodOfReport>
<notSubjectToSection16> 0 </notSubjectToSection16>
<issuer>
<issuerCik> 0001042418 </issuerCik>
<issuerName> Inhibitor Therapeutics, Inc. </issuerName>
<issuerTradingSymbol> INTI </issuerTradingSymbol>
</issuer>
<reportingOwner>
<reportingOwnerId>
<rptOwnerCik> 0001611535 </rptOwnerCik>
<rptOwnerName> Mayne Pharma Ventures Pty Ltd </rptOwnerName>
</reportingOwnerId>
<reportingOwnerAddress>
<rptOwnerStreet1> 1538 MAIN NORTH ROAD </rptOwnerStreet1>
<rptOwnerStreet2></rptOwnerStreet2>
<rptOwnerCity> SALISBURY SOUTH, SA </rptOwnerCity>
<rptOwnerState> C3 </rptOwnerState>
<rptOwnerZipCode> 5106 </rptOwnerZipCode>
<rptOwnerStateDescription> AUSTRALIA </rptOwnerStateDescription>
</reportingOwnerAddress>
<reportingOwnerRelationship>
<isDirector> 0 </isDirector>
<isOfficer> 0 </isOfficer>
<isTenPercentOwner> 1 </isTenPercentOwner>
<isOther> 0 </isOther>
<officerTitle></officerTitle>
<otherText></otherText>
</reportingOwnerRelationship>
</reportingOwner>
<reportingOwner>
<reportingOwnerId>
<rptOwnerCik> 0001611534 </rptOwnerCik>
<rptOwnerName> Mayne Pharma International Pty Ltd </rptOwnerName>
</reportingOwnerId>
<reportingOwnerAddress>
<rptOwnerStreet1> 1538 MAIN NORTH ROAD </rptOwnerStreet1>
<rptOwnerStreet2></rptOwnerStreet2>
<rptOwnerCity> SALISBURY SOUTH, SA </rptOwnerCity>
<rptOwnerState> C3 </rptOwnerState>
<rptOwnerZipCode> 5106 </rptOwnerZipCode>
<rptOwnerStateDescription> AUSTRALIA </rptOwnerStateDescription>
</reportingOwnerAddress>
<reportingOwnerRelationship>
<isDirector> 0 </isDirector>
<isOfficer> 0 </isOfficer>
<isTenPercentOwner> 1 </isTenPercentOwner>
<isOther> 0 </isOther>
<officerTitle></officerTitle>
<otherText></otherText>
</reportingOwnerRelationship>
</reportingOwner>
<reportingOwner>
<reportingOwnerId>
<rptOwnerCik> 0001560183 </rptOwnerCik>
<rptOwnerName> Mayne Pharma Group Ltd </rptOwnerName>
</reportingOwnerId>
<reportingOwnerAddress>
<rptOwnerStreet1> 1538 MAIN NORTH ROAD </rptOwnerStreet1>
<rptOwnerStreet2></rptOwnerStreet2>
<rptOwnerCity> SALISBURY SOUTH, SA </rptOwnerCity>
<rptOwnerState> C3 </rptOwnerState>
<rptOwnerZipCode> 5106 </rptOwnerZipCode>
<rptOwnerStateDescription> AUSTRALIA </rptOwnerStateDescription>
</reportingOwnerAddress>
<reportingOwnerRelationship>
<isDirector> 0 </isDirector>
<isOfficer> 0 </isOfficer>
<isTenPercentOwner> 1 </isTenPercentOwner>
<isOther> 0 </isOther>
<officerTitle></officerTitle>
<otherText></otherText>
</reportingOwnerRelationship>
</reportingOwner>
<nonDerivativeTable>
<nonDerivativeTransaction>
<securityTitle>
<value> Common Stock </value>
</securityTitle>
<transactionDate>
<value> 2021-01-15 </value>
</transactionDate>
<deemedExecutionDate></deemedExecutionDate>
<transactionCoding>
<transactionFormType> 4 </transactionFormType>
<transactionCode> J </transactionCode>
<equitySwapInvolved> 0 </equitySwapInvolved>
<footnoteId id="F1"/>
</transactionCoding>
<transactionTimeliness></transactionTimeliness>
<transactionAmounts>
<transactionShares>
<value> 2240488 </value>
</transactionShares>
<transactionPricePerShare>
<value> 0 </value>
</transactionPricePerShare>
<transactionAcquiredDisposedCode>
<value> A </value>
</transactionAcquiredDisposedCode>
</transactionAmounts>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value> 204083227 </value>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value> D </value>
<footnoteId id="F2"/>
</directOrIndirectOwnership>
</ownershipNature>
</nonDerivativeTransaction>
</nonDerivativeTable>
<footnotes>
<footnote id="F1"> On January 15, 2021, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") received a dividend of 2,240,488 shares of Common Stock paid by the Issuer on shares of Series B Convertible Preferred Stock held by Mayne Ventures, pursuant to the terms of such Series B Convertible Preferred Stock. </footnote>
<footnote id="F2"> These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures may be deemed to be a director by deputization by virtue of its representation on the Board of Directors of the Issuer. </footnote>
</footnotes>
<ownerSignature>
<signatureName> Mayne Pharma Ventures Pty Ltd, By: /s/ Scott Richards, Director </signatureName>
<signatureDate> 2021-01-18 </signatureDate>
</ownerSignature>
<ownerSignature>
<signatureName> Mayne Pharma International Pty Ltd, By: /s/ Scott Richards, Director </signatureName>
<signatureDate> 2021-01-18 </signatureDate>
</ownerSignature>
<ownerSignature>
<signatureName> Mayne Pharma Group Limited: /s/ Scott Richards, Director </signatureName>
<signatureDate> 2021-01-18 </signatureDate>
</ownerSignature>
</ownershipDocument>


↑Top
Filing Submission 0001104659-21-005226   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sat., May 4, 3:57:29.2am ET